MM

The Alkaline Water Company Reports 62% Year-Over-Year Drop in Net Loss in First Quarter of Fiscal Year 2024, Continues Significant Steps Toward Profitability

Retrieved on: 
Friday, September 22, 2023
Retail, Other Natural Resources, Convenience Store, Supermarket, Natural Resources, Food, Beverage, OPEX, MM, Fiscal, Yoy, Delicious (website), Security (finance)

The Alkaline Water Company Inc. (NASDAQ: WTER) (the “Company”), the country’s largest independent Alkaline water company, today announced its results for the quarter ended June 30, 2023 that continue to show the execution of its pathway to profitability.

Key Points: 
  • The Alkaline Water Company Inc. (NASDAQ: WTER) (the “Company”), the country’s largest independent Alkaline water company, today announced its results for the quarter ended June 30, 2023 that continue to show the execution of its pathway to profitability.
  • The Company reported a net loss of ($2,840,938), a 62% improvement year-over-year with net loss per share improving by 71% year-over-year.
  • Effective April 5, 2023, The Company effected a one for fifteen reverse stock split of its authorized, issued and outstanding shares of common stock.
  • Accordingly, all share and per-share amounts referenced above for the current period and prior periods have been adjusted to reflect the reverse stock split.

SEQSTER CEO Ardy Arianpour Named to PharmaVoice 100 for Innovation in Life Sciences

Retrieved on: 
Tuesday, September 19, 2023
Research, Technology, Hospitals, Health Technology, Health Insurance, Software, Practice Management, Health, Data Management, Science, Journal of Medical Marketing, Real, Medicine, Drug development, Senior, Genomics, Life, Multimedia, SCOTUS, Patient, Marketing, Konica, Boehringer Ingelheim, San Diego Business Journal, Organization, Genetics, MM, Genetic testing, NPF, United, BRCA, CO, UBC, Industry Dive, Conference, Caregiver, Pharmaceutical industry, Takeda, Media, Trailblazer

Seqster PDM, Inc. (" SEQSTER "), the leading healthcare technology company, today announced CEO and Co-Founder Ardy Arianpour has been named to the prestigious 2023 PharmaVoice 100, a recognition of the 100 most inspiring people in the life sciences industry.

Key Points: 
  • Seqster PDM, Inc. (" SEQSTER "), the leading healthcare technology company, today announced CEO and Co-Founder Ardy Arianpour has been named to the prestigious 2023 PharmaVoice 100, a recognition of the 100 most inspiring people in the life sciences industry.
  • View the full release here: https://www.businesswire.com/news/home/20230919462255/en/
    Ardy Arianpour has been named to the prestigious 2023 PharmaVoice 100, a recognition of the 100 most inspiring people in the life sciences industry.
  • Throughout a distinguished 20-year career in the life sciences sector, Ardy Arianpour has consistently demonstrated a relentless dedication to driving innovation and introducing disruptive products for both patients and researchers.
  • PharmaVoice will recognize this year's honorees at the 2023 PharmaVoice 100 Exclusive Event: “The NextFrontier of the Life Sciences” on Oct. 25-26.

Institute for Myeloma & Bone Cancer Research Announces Publication in Targeted Oncology

Retrieved on: 
Tuesday, September 19, 2023
Multiple myeloma, MM, Survival, Science, MD, Patient, Pharmaceutical industry, Dentistry

WEST HOLLYWOOD, Calif., Sept. 19, 2023 /PRNewswire/ -- The Institute for Myeloma & Bone Cancer Research (IMBCR) announces the publication in Targeted Oncology on the outstanding survival of 161 unselected, new patients with multiple myeloma (MM) who started treatment from 2006 to 2022 at Berenson Cancer Center. 

Key Points: 
  • WEST HOLLYWOOD, Calif., Sept. 19, 2023 /PRNewswire/ -- The Institute for Myeloma & Bone Cancer Research (IMBCR) announces the publication in Targeted Oncology on the outstanding survival of 161 unselected, new patients with multiple myeloma (MM) who started treatment from 2006 to 2022 at Berenson Cancer Center.
  • It is the longest reported in any population of unselected, newly diagnosed multiple myeloma patients.
  • While myeloma care centers consider stem cell transplant as the standard first treatment, none of the patients in this clinical setting received a stem cell transplant.
  • This comprehensive and personalized approach by a forward-thinking myeloma expert has resulted in publication of the longest survival reported to date.

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month

Retrieved on: 
Monday, September 18, 2023
Human, Acute lymphoblastic leukemia, Senior, ALL, Mantle cell lymphoma, Myelodysplastic syndrome, Malignancy, Bone marrow, Research, Hodgkin lymphoma, Doctor of Philosophy, National Comprehensive Cancer Network, NCCN, MDS, Congress, CAR, AML, Patient, SAN, Hematology, MM, Memorial Sloan Kettering Cancer Center, MCL, Acute leukemia, Conference, Acute myeloid leukemia, Chronic myelogenous leukemia, Multiple myeloma, Vaccine, Rare-earth element, Primary myelofibrosis, MD

SAN FRANCISCO, Sept. 18, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the first time since 2019. The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.

Key Points: 
  • The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.
  • NCCN 2023 Annual Congress: Hematologic Malignancies is taking place September 22-23, 2023.
  • "This will help us all to achieve the best possible outcomes for people with blood cancer in a rapidly evolving landscape."
  • Save the dates: the NCCN 2024 Annual Conference will be happening in Orlando, FL April 5 - 7, 2024.

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month

Retrieved on: 
Monday, September 18, 2023
Human, Acute lymphoblastic leukemia, Senior, ALL, Mantle cell lymphoma, Myelodysplastic syndrome, Malignancy, Bone marrow, Research, Hodgkin lymphoma, Doctor of Philosophy, National Comprehensive Cancer Network, NCCN, Hilton San Francisco Union Square, MDS, Congress, CAR, AML, Patient, SAN, Hematology, MM, Memorial Sloan Kettering Cancer Center, MCL, Acute leukemia, Conference, Acute myeloid leukemia, Chronic myelogenous leukemia, Multiple myeloma, Vaccine, Primary myelofibrosis, MD

SAN FRANCISCO, Sept. 18, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the first time since 2019. The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.

Key Points: 
  • The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
  • "We designed a comprehensive program for the entire hematology and oncology team—taking into account the latest advances, conversations, and controversies in blood cancer treatment today," said congress Chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center.
  • "This will help us all to achieve the best possible outcomes for people with blood cancer in a rapidly evolving landscape."
  • Save the dates: the NCCN 2024 Annual Conference will be happening in Orlando, FL April 5 - 7, 2024.

Young Entrepreneur Breaks Boundaries with Ecological Improvements' Exceptional Achievements in 2023

Retrieved on: 
Monday, September 11, 2023
Sports, Manufacturing, Construction & Property, Professional Services, Landscape, Golf, Other Manufacturing, Environment, Human Resources, Other Construction & Property, Sustainability, MM, River, Motion, Erosion, Multimedia, Pond, Lake, EI

At just 26 years old, the dynamic entrepreneur and founder of Ecological Improvements (Ei) has defied all odds, shattering industry expectations with the company's remarkable achievements this year.

Key Points: 
  • At just 26 years old, the dynamic entrepreneur and founder of Ecological Improvements (Ei) has defied all odds, shattering industry expectations with the company's remarkable achievements this year.
  • The overwhelmingly positive response we've encountered, especially from the Carolinas, reinforces our belief in the importance of proactive erosion control.
  • It's truly impressive to see such a young company, led by an equally young entrepreneur, maintaining such outstanding financial prowess.
  • Their avant-garde technologies and an unwavering resolve for excellence have cemented their position as a trusted partner across the US.

Nicola Mining Inc. Signs Letter of Intent with Nittetsu Mining Co. Ltd. for Exploration at New Craigmont Copper Project

Retrieved on: 
Wednesday, September 6, 2023
Shin Nittetsu-mae Station, Treasure Mountain, Electricity, Property, FSE, Sale, LOI, Coal, Renewable energy, Republic, National instrument, Transaction, Mining, MM, Project, Copper, News, Cryptocurrency, Commercial property

The total aggregate $25.0 MM contribution by Nittetsu would value the New Craigmont Project at $62.5 MM would garner Nittetsu a 40% interest in the New Craigmont Copper Project.

Key Points: 
  • The total aggregate $25.0 MM contribution by Nittetsu would value the New Craigmont Project at $62.5 MM would garner Nittetsu a 40% interest in the New Craigmont Copper Project.
  • Peter Espig, CEO of Nicola, commented, "We are very excited to be working with Nittetsu, which brings a great deal of experience and credibility to our New Craigmont Copper Project.
  • We are also very excited to know that the Project is Nittetsu's first foray into a British Columbia based copper project."
  • Nittetsu operates Atacama Copper Mine and currently in the process of developing a second copper mine in the Republic of Chile.

Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting

Retrieved on: 
Wednesday, September 6, 2023
MM, Poster, Half-life, Therapy, Patient, SAN, IMS, BCMA, EEST, Annual general meeting, Vaccine

The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.

Key Points: 
  • The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.
  • ET, Presentation – 12:30 to 13:30 EEST / 5:30 a.m. to 6:30 a.m.
  • ET
    The poster will also be available on Harpoon’s website following the presentation.
  • For more details about the IMS Annual Meeting, please visit:

CKGSB Professor Launches MM Chinese Art Indices to Aid Art Investment Decisions

Retrieved on: 
Tuesday, September 5, 2023
Sotheby's, Acertus Market Sentiment Indicator, Greater, CKGSB, Shanghai Academy of Social Sciences, COVID-19, Social science, Sale, Christie's, University of Michigan Consumer Sentiment Index, MM, Growth, Management, Auction, Index, New York University

BEIJING, Sept. 5, 2023 /PRNewswire/ -- CKGSB Professor of Finance Mei Jianping launches the MM Chinese Art Indices , a biannual reference guide that determines the changing dynamics of the Chinese art market by measuring repeat auction sales.

Key Points: 
  • BEIJING, Sept. 5, 2023 /PRNewswire/ -- CKGSB Professor of Finance Mei Jianping launches the MM Chinese Art Indices , a biannual reference guide that determines the changing dynamics of the Chinese art market by measuring repeat auction sales.
  • By measuring prices, sentiment, liquidity and artists' popularity, the Indices offer a scientific, systematic and comparable system on which to evaluate investment decisions regarding Chinese art, a black box to many in the art investment world.
  • With the Indices, investors can apply reason to the valuation of Chinese art, which in turn may help the market grow at a sustainable pace.
  • The biannual MM Chinese Art Indices are co-developed by CKGSB Professor Mei Jiangping; Michael Moses, a retired professor at New York University; and Jiang Guolin, a retired researcher at the Shanghai Academy of Social Sciences.

CKGSB Professor Launches MM Chinese Art Indices to Aid Art Investment Decisions

Retrieved on: 
Tuesday, September 5, 2023
Sotheby's, Acertus Market Sentiment Indicator, Greater, CKGSB, Shanghai Academy of Social Sciences, COVID-19, Social science, Sale, Christie's, University of Michigan Consumer Sentiment Index, MM, Growth, Management, Auction, Index, New York University

BEIJING, Sept. 5, 2023 /PRNewswire/ -- CKGSB Professor of Finance Mei Jianping launches the MM Chinese Art Indices , a biannual reference guide that determines the changing dynamics of the Chinese art market by measuring repeat auction sales.

Key Points: 
  • BEIJING, Sept. 5, 2023 /PRNewswire/ -- CKGSB Professor of Finance Mei Jianping launches the MM Chinese Art Indices , a biannual reference guide that determines the changing dynamics of the Chinese art market by measuring repeat auction sales.
  • By measuring prices, sentiment, liquidity and artists' popularity, the Indices offer a scientific, systematic and comparable system on which to evaluate investment decisions regarding Chinese art, a black box to many in the art investment world.
  • With the Indices, investors can apply reason to the valuation of Chinese art, which in turn may help the market grow at a sustainable pace.
  • The biannual MM Chinese Art Indices are co-developed by CKGSB Professor Mei Jiangping; Michael Moses, a retired professor at New York University; and Jiang Guolin, a retired researcher at the Shanghai Academy of Social Sciences.